Introduction: Liver injury induced by drugs is a serious clinical problem. Many circulating
biomarkers for identifying and predicting drug-induced liver injury (DILI) have been …

Mitigating the risk of drug hypersensitivity reactions is an important facet of a given
pharmaceutical, with poor performance in this area of safety often leading to warnings …

An emerging clinical issue associated with immune-oncology agents is the collateral effects
on the tolerability of concomitant medications. One report of this phenomenon was the …

Drug-responsive T-cells are activated with the parent compound or metabolites, often via
different pathways (pharmacological interaction and hapten). An obstacle to the …

In vitro preclinical drug-induced liver injury (DILI) risk assessment relies largely on the use of
hepatocytes to measure drug-specific changes in cell function or viability. Unfortunately, this …

Drug rash with eosinophilia with systemic symptoms (DRESS) is a serious adverse event
associated with use of the glycopeptide antibiotic vancomycin. Vancomycin-induced drug …

Allergic contact dermatitis is a widespread T cell-mediated inflammatory skin disease, but in
vitro monitoring of chemical-specific T cells remains challenging. We here introduce short …

Drugs can activate different cells of the immune system and initiate an immune response
that can lead to life-threatening diseases collectively known as severe cutaneous adverse …

It is becoming increasingly apparent that tolerance mechanisms impact on susceptibility to
drug hypersensitivity. As the field moves forward it will be interesting to discover whether …

Allergic reactions to drugs and chemicals are mediated by an adaptive immune response
involving specific T cells. During thymic selection, T cells that have not yet encountered their …